Industries:

1. Life Sciences
2. Clinical Diagnostics

TOP 3 Markets:

1. USA: approx. 45%
2. Europe: approx. 30%
3. Asia-Pacific: approx. 20%

Bio-Rad Laboratories, Inc. generates its revenues mainly from two major segments: Life Sciences and Clinical Diagnostics. These two areas cover a wide range of products and services used in research and clinical applications.

The largest market for Bio-Rad is the USA, accounting for about 45% of revenue. This is due to the strong presence and high demand for life science and diagnostic solutions. Europe follows with a share of about 30%, where there is also a strong demand for innovative diagnostic solutions. The Asia-Pacific region, especially countries like China and Japan, contributes about 20% to revenue and shows a growing interest in advanced life science technologies.

Production Sites:

• USA
• Europe
• Asia

Bio-Rad Laboratories, Inc. produces its products at several locations worldwide. The main production facilities are located in the USA, particularly in California. Additionally, the company has production capacities in Europe, including in Switzerland, and in Asia to efficiently serve the demand in these markets.

This geographical diversification enables Bio-Rad to optimize production costs and reduce delivery times for customers in different regions.

Focus on Innovation and Research: Bio-Rad Laboratories continuously invests in research and development to bring innovative products to the market.

Expansion of Product Portfolio: The company plans to expand its product offering through strategic acquisitions and partnerships, especially in the areas of clinical diagnostics and life sciences.

Global Market Expansion: Bio-Rad aims to strengthen its presence in emerging markets to benefit from the increasing demand for medical diagnostic solutions.

Bio-Rad Laboratories relies on a combination of internal innovation and strategic acquisitions to strengthen its market position and unlock new growth opportunities. By focusing on research and development and entering new markets, the company aims to significantly increase its revenues and market shares in the coming years.

Main raw materials: Chemicals, plastics, metals

Countries of origin: USA, China, Germany, Japan

Bio-Rad Laboratories, Inc. imports a variety of raw materials and materials that are necessary for the production of their products. These include specialized chemicals, plastics, and metals that are used in the production of laboratory equipment and diagnostic products.

The USA and China are significant suppliers of chemicals and plastics, while Germany and Japan are known for high-quality metals and specialized components. These countries provide the necessary materials to ensure Bio-Rad's high quality standards.

By diversifying their supply chains, Bio-Rad ensures that they can flexibly respond to market changes and secure the supply of critical materials.

Market Share: 10% in the Life Sciences sector (2024, estimate)
R&D Investments: 9.8% of revenue (2023)
Gross Margin: 55% (2023)

Bio-Rad Laboratories, Inc. has a significant competitive advantage in the Life Sciences and clinical diagnostics sector, supported by continuous investments in research and development. With nearly 10% market share in the Life Sciences sector, the company positions itself as one of the leading players, backed by a strong innovation pipeline and strategic partnerships.

The 55% gross margin demonstrates effective cost control and the ability to offer high-quality products at a competitive price. This enables Bio-Rad to remain profitable in a highly competitive market environment.

Additionally, the company benefits from its global presence and a diversified product portfolio, allowing it to better navigate market fluctuations and capitalize on new growth opportunities.

Institutional Investor Share: approximately 85% (estimated 2025)
Insider Purchases/Sales: No significant insider transactions in the last year (estimated 2025)

The institutional investor share at Bio-Rad Laboratories, Inc. remains high, indicating the confidence of large investors in the company's long-term stability and growth prospects.

In 2025, there were no significant insider purchases or sales, suggesting that the management and other insiders are satisfied with the current company strategy and do not expect any short-term changes. This can be seen as a positive signal for the stability and confidence in the company's future development.

Market share of Bio-Rad Laboratories, Inc.: Estimated 5-7% (2025)

Top competitors and their market shares:

1. Thermo Fisher Scientific Inc. - approx. 15%
2. Danaher Corporation - approx. 12%
3. Roche Diagnostics - approx. 10%
4. Abbott Laboratories - approx. 8%
5. Bio-Rad Laboratories, Inc. - approx. 5-7%
6. Agilent Technologies - approx. 5%
7. Siemens Healthineers - approx. 4%
8. PerkinElmer - approx. 3%
9. Illumina - approx. 3%
10. Qiagen - approx. 2%

Moat of Bio-Rad Laboratories, Inc.:

Bio-Rad Laboratories has a moderate moat, mainly based on its strong position in the field of life science research and clinical diagnostics. The company benefits from a wide range of products and an established customer base in research institutions and clinics worldwide.

Compared to its competitors such as Thermo Fisher Scientific and Danaher, which have larger resources and more comprehensive product portfolios, Bio-Rad's moat is less pronounced. These companies have significant competitive advantages due to their size, innovation capabilities, and global distribution networks.

Thermo Fisher Scientific and Danaher have solidified their market leadership through strategic acquisitions and continuous innovations, giving them a stronger moat. Bio-Rad must continuously invest in research and development to maintain its position and strengthen its moat.

Revenue Growth: 7.5% (2024) Research and Development Ratio: 10% of revenue (2024) Market Share in the Biotechnology Industry: 5% (2024)

Bio-Rad Laboratories, Inc. recorded a revenue growth of 7.5% in 2024, indicating strong demand for its biotechnological products and services. The company continuously invests in research and development, reinvesting 10% of its revenue in this area. This suggests a strategic focus on driving innovation and remaining competitive in the long term.

With a 5% market share in the biotechnology industry, Bio-Rad demonstrates a solid positioning. The company benefits from a diversified product portfolio and a global presence, making it resilient to market fluctuations. Analysts see potential for further growth in the continuous investment in new technologies and the exploration of new markets.

In summary, Bio-Rad Laboratories could represent an attractive investment opportunity, especially for investors focusing on long-term growth and innovation.

Dividend payment: No dividend (as of 2023)

Bio-Rad Laboratories, Inc. traditionally does not pay a dividend to its shareholders. The company has focused on reinvesting its profits in research and development as well as strategic acquisitions to promote long-term growth.

This strategy reflects the goal of increasing the company's value through innovation and expansion, rather than making short-term payouts to shareholders. Investors who invest in Bio-Rad typically do so with a focus on capital growth rather than dividend yields.